

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	BENITEC BIOPHARMA LIMITED
ABN	64 068 943 662

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR PETER FRENCH
Date of last notice	26 August 2013 (Appendix 3X)

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Peter French & L French
Date of change	5 March 2014
No. of securities held prior to change	Direct 304,895 Ordinary shares 49,231 Unlisted options exercise price \$0.325 expiry 18 February 2015 1,200,000 Unlisted Options exercise price \$1.25 expiry 17 November 2016 200,000 Unlisted Options exercise price \$0.51 expiry 19 August 2014 Indirect – Dr Peter French & L French 27,720 Ordinary shares
Class	as above
Number acquired	Indirect 9,939 Ordinary shares
Number disposed	nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$19,996
No. of securities held after change	Direct 304,895 Ordinary shares 49,231 Unlisted options exercise price \$0.325 expiry 18 February 2015 1,200,000 Unlisted Options exercise price \$1.25 expiry 17 November 2016 200,000 Unlisted Options exercise price \$0.51 expiry 19 August 2014 Indirect – Dr Peter French & L French 37,659 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market purchase

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.